Shu-Fen Fang, Wen-Wen Peng, Yuan-Zhen Xiong, Xu-Liang Nie* and Jian-Ping Huang*

Crystal structure of 3-(2-chloro-benzyl)-7-[4-(2-chloro-benzyl)-piperazin-1-yl]-5,6,8-trifluoro-3H-quinazolin-4-one, C_{26}H_{21}Cl_{2}F_{3}N_{4}O

https://doi.org/10.1515/ncrs-2021-0085
Received March 9, 2021; accepted March 30, 2021; published online May 3, 2021

Abstract
C_{26}H_{21}Cl_{2}F_{3}N_{4}O, monoclinic, Pc (no. 7), a = 21.218(6) Å, b = 5.9599(16) Å, c = 9.439(3) Å, β = 99.295(3)°, V = 1177.9(5) Å³, Z = 2, R_{gt}(F) = 0.0471, wR_{ref}(F^2) = 0.1282, T = 296(2) K.

CCDC no.: 2074197

Table 1: Data collection and handling.

| Crystal: | Colourless plate |
| Size: | 0.22 × 0.18 × 0.15 mm |
| Wavelength: | Mo Kα radiation (0.71073 Å) |
| μ: | 0.33 mm^{-1} |
| Diffractometer, scan mode: | Bruker APEX-II, φ and ω |
| R_{max}, completeness: | 25.5°, 99% |
| N(hkl)_{measured}, N(hkl)_{unique}, R_{int}: | 4178, 4178, |
| Criterion for I_{obs}, N(hkl)_{gt}: | I_{obs} > 2 σ(I_{obs}), 3955 |
| N(param)$_{refined}$: | 326 |
| Programs: | Bruker [1], SHELX [2, 3], Diamond [4] |

The molecular structure is shown in the Figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Source of material
To a stirred solution of 5,6,8-trifluoro-7-piperazin-1-yl-3H-quinazolin-4-one (28.42 g, 0.10 mol) in ethanol (140 mL) was in turn added 1-bromomethyl-2-chloro-benzene (41.10 g, 0.20 mol) and sodium hydroxide (8.00 g, 0.20 mol), and then the reaction mixture was refluxed for about 5 h. After the reaction was found to be completed (monitored by TLC), the ethanol was distilled at reduced pressure to give the
crude product. The crude product was poured into water (30 mL) and extracted with EtOAc (50 mL * 3). The EtOAc solvent was evaporated to provide the title compound as crystals suitable for X-ray diffraction analysis in 95.3% yield. 1H NMR (400 MHz, CDCl3) δ 2.44–2.468 (t, J = 4.8 Hz, 4 H, PhN(CH2)3), 3.230–3.254 (t, J = 4.8, Hz, 4 H, BnN(CH2)3), 3.476 (s, 2 H, NCH2), 5.014 (s, 2 H, OCNCH2), 6.987–7.298 (m, 8 H, PhH), 7.934 (s, 1 H, NCHN) ppm. 13C NMR (100 MHz, CDCl3) δ = 156.30, 146.58, 133.77, 132.98, 131.80, 130.58, 130.22, 129.19, 128.84, 127.73, 126.69, 125.99, 101.28, 58.52, 52.67, 49.97, 46.74, 28.97 ppm.

**Experimental details**

All H atoms were included in calculated positions and refined as riding atoms, with O–H = 0.82 Å with Uiso(H) = 1.2 Ueq(O), C–H = 0.93–0.98 Å with Uiso(H) = 1.2–1.5 Ueq(C) [3].

**Comment**

KRAS mutations have been ubiquitous in human cancers [5]. Because of the missense mutation of KRAS at codon 12, the protein are aberrantly activated into a hyperexcitable state by attenuating its GTPase activity resulting in accretion of GTP-bound activated KRAS and activation of downstream signaling pathways [6–9]. KRAS p.G12C mutations are dominant in NSCLC and exist in 11–16% of lung adenocarcinomas (45–50% of mutant KRAS is p.G12C), as well as 1–4% of pancreatic and colorectal adenocarcinomas respectively [10–13]. KRAS G12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S–II P). As accessibility of the S–II P being restricted only to the GDP-bound state, the success of abovementioned approach requires active cycling of KRAS G12C between its active–GTP and inactive–GDP conformations [14]. The active cycling has been realized by these compounds, which possess a quinazoline core as a versatile lead scaffold following systematic optimization of substituent around the scaffold to achieve rapid and sustained in vitro and in vivo target occupancy to induce tumor regression [14, 15].

Recently, an impactful and high-yielding method for the
synthesis of quinazolines is developed in our group, and crystals of several key compounds have been achieved. Herein, the synthesis and crystal structure of a key compound 3-(2-chloro-benzyl)-7-(4-(2-chloro-benzyl)-piperazin-1-yl)-5,6,8-trifluoro-3H-quinazolin-4-one is disclosed.

There is one molecule in the asymmetric unit (shown in the figure). In the crystal structure of the title compound bond lengths and angles are very similar to those given in the literature for 3-benzyl-7-chloro-2-isobutylquinazolin-4(3H)-one [16].

The molecule consists of four moieties: quinoline, piperazin ring and two chlorobenzyl groups. The quinoline ring is connected to the nitrogen atom (N3) of piperazin ring. Two benzyis are connected to the nitrogen atom (N4) of piperazin ring and the nitrogen atom (N2) of the quinoline ring, respectively. The atoms of the quinoline and the two chlorobenzyl moieties are coplanar, and piperazin ring is in a typical chair configuration. The torsion angles of C21–C20–N4–C18 and C20–N4–C18–C19 are 76.6(6)° and 175.3(5)°, respectively.

Acknowledgements: X-ray data were collected at Instrumental Analysis Center Nanchang Hangkong University, Nanchang, 330063, People’s Republic of China.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Natural Science Foundation of Science and Technology Department of Jiangxi Province (No. 2015BBF60081; 2017BBE50027; 2017BBG70029; 2020BBE153028), Natural Science Foundation of Education Department of Jiangxi Province (No. GJJ170275; GJJ200404), Natural Science Foundation of Nanchang City (2018CXTD014), and Natural Science Foundation of Jiangxi Agriculture University (No. 201610410007; 201610410079).

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References